---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115592"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-10-18T23:59:59+00:00"
generated_at: "2026-05-30T12:46:51.022535+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days

## Summary
- Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.
- Has 180 calendar days (until April 14, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
- May seek stockholder approval for reverse stock split if needed to cure deficiency.
- Also plans to file new $300M shelf registration S-3 to replace expiring 2021 registration.
- If not compliant by deadline, may transfer to Nasdaq Capital Market for additional 180-day cure period.

## SEC filing metadata
- accession: 0000950170-24-115592
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-10-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024115592/0000950170-24-115592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024115592/atha-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115592
- JSON: https://secwatch.observer/filing/0000950170-24-115592.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.